Early Access Program With Inolimomab in Steroid-refractory Acute Graft Versus Host Disease

AVAILABLEEXPANDED_ACCESS
Timeline

Start Date

Not specified

Conditions
Steroid Resistant Acute Graft Versus Host Disease
Interventions
BIOLOGICAL

inolimomab

"1 or 2 Induction Phases at 0.3 mg/kg/day for adults or 0.4 mg/kd/day for children over 8 consecutive days If no complete response (CR) occurs after 8 days, a second induction phase is conducted until day 16 (even if CR is obtained before completion of the second induction phase).~Maintenance Phase: 0.4 mg/kg administered 3 times a week until Day 28 In case of a CR at day 9, the maintenance phase will start after day 9 and will be sustained until day 28.~In case of a CR, partial response (PR) or mixed response (MR) at day 17, the maintenance phase will start after day 17 and will be sustained until day 28.~Total duration of treatment is 28 ±2 days."

Trial Locations (1)

Unknown

AVAILABLE

ElsaLys Biotech, Lyon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

ElsaLys Biotech

INDUSTRY